Racial Disparities in Access to Novo Nordisk's Diabetes Drugs Among U.S. Veterans

A study reveals racial and ethnic disparities in access to Novo Nordisk's diabetes and weight loss drugs among U.S. military veterans. Black, Asian, and Native American patients are less likely to receive semaglutide compared to white veterans, despite equal healthcare access at VA facilities. Researchers urge policy adjustments.

A recent study highlights racial and ethnic inequalities in access to Novo Nordisk's highly sought-after diabetes and weight loss medications among U.S. military veterans. Published on Veterans Day, the report examines patient data from the U.S. Veterans Affairs Medical System.

Dr. Rebecca Tisdale, leading the research at the VA Palo Alto Health Care System, reported that Black, Asian, and Native American patients are disproportionately underserved concerning semaglutide prescriptions compared to white veterans. Semaglutide, sold as Ozempic and Wegovy, is used to treat type 2 diabetes and manage weight.

Analyzing data from 1.9 million overweight and obese veterans, the study found significant disparities. Black patients had a 26% lower chance of receiving semaglutide if diabetic. Similar discrepancies were noted among Asian and Native American patients. Researchers emphasized the critical need for equity-focused policy revisions as the demand for these treatments grows.

(With inputs from agencies.)